Related Experiment Video

Updated: Jun 21, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K

Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer

Léa Mercier1, Matthieu Delaye1, Alina Fuerea1

  • 1Gustave Roussy, Department Of Medical Oncology, 94800 Villejuif, France.

European Journal of Cancer (Oxford, England : 1990)
|July 12, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

331

Related Experiment Videos

Last Updated: Jun 21, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.7K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay
05:21

Author Spotlight: Optimizing Antibody-Based Cancer Treatments via Antibody-Dependent, Cell-Mediated Cytotoxicity Assay

Published on: September 13, 2024

331

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

Articles linked to this work by shared authors, journal, and citation graph.

Perceptions of the environmental impact of oncology care: A cross-sectional survey of French and Belgian healthcare professionals.

The journal of climate change and health·2026

[Metastatic or unresectable recurrent anal canal cancer: Therapeutic approaches and emerging perspectives].

Bulletin du cancer·2026

Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort).

JHEP reports : innovation in hepatology·2026

Prognostic Impact of Concomitant Genomic Alterations in FGFR2-Positive Cholangiocarcinoma Treated With Pemigatinib.

Liver international : official journal of the International Association for the Study of the Liver·2026

Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective.

Cancer treatment reviews·2026

Outcomes of patients treated by FGFR inhibitors according to alteration types: An agnostic monocentric retrospective cohort.

European journal of cancer (Oxford, England : 1990)·2026

Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study.

European journal of cancer (Oxford, England : 1990)·2026

Direct Tumor-Adipocyte Contact as a Prognostic Biomarker in Resected Pancreatic Ductal Adenocarcinoma.

European journal of cancer (Oxford, England : 1990)·2026

Biomarker-defined benefit from FLOT plus nivolumab in metastatic gastroesophageal cancer: Extended follow-up and immune-inflammatory markers of the phase II IKF-AIO-moonlight trial.

European journal of cancer (Oxford, England : 1990)·2026

Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study.

European journal of cancer (Oxford, England : 1990)·2026

Geneo study: Comprehensive genomic profiling versus limited local reimbursed NGS panels within the belgian Precision initiative.

European journal of cancer (Oxford, England : 1990)·2026

Assessing the effect of chemotherapy dose reductions and time delay on event-free survival in Ewing Sarcoma: A retrospective analysis of the Euro Ewing 2012 trial.

European journal of cancer (Oxford, England : 1990)·2026

Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.

Cancer discovery·2026

Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review.

Immunological medicine·2026

Navigating clozapine discontinuation in clinical practice: An updated framework.

Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists·2026

Early progression after immune checkpoint inhibitor therapy in recurrent or metastatic head and neck squamous cell carcinoma: association with disease distribution in a single-center retrospective study.

Japanese journal of clinical oncology·2026

Evaluation of the protective effects of green tea for ischemia-reperfusion injury in rat ovary tissue: an experimental study.

Acta cirurgica brasileira·2026

Early intervention with clozapine: Is there a neurobiological critical period for treatment-resistant schizophrenia?

Journal of psychopharmacology (Oxford, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us